|1.||Davis, Teresa A: 3 articles (01/2014 - 08/2007)|
|2.||Suryawan, Agus: 3 articles (01/2014 - 08/2007)|
|3.||Nguyen, Hanh V: 3 articles (01/2014 - 08/2007)|
|4.||Viollet, Benoit: 3 articles (06/2013 - 02/2007)|
|5.||Fukuda, Mari: 2 articles (05/2014 - 05/2009)|
|6.||Nakatsuka, Shin-Ichi: 2 articles (05/2014 - 05/2009)|
|7.||Tatsumi, Naoya: 2 articles (05/2014 - 05/2009)|
|8.||Fujiki, Fumihiro: 2 articles (05/2014 - 05/2009)|
|9.||Fukuda, Ikuyo: 2 articles (05/2014 - 05/2009)|
|10.||Nanchi, Isamu: 2 articles (05/2014 - 05/2009)|
10/01/1989 - "The method is very useful for monitoring changing levels of EF-2 during various pathological and biological processes, including cell cycle, ageing, cancer and other diseases."
02/01/1991 - "Ten tumors were "typical" in both respects: 2 closely corresponded to MZ, 5 to EF, 2 to FC and 1 to PC. "
08/01/1983 - "Cells were grown as tumors in hamsters and EF-2 was purified from tissue homogenates by column chromatography. "
01/01/1983 - "Data also show that the amount of EF-2 bound to the monoribosomal fraction isolated from tumor cells is significantly and constantly lower than that of the corresponding fraction isolated from reticulocytes or hepatocytes. "
01/01/1983 - "In contrast, the EF-2 content of the polyribosomal fraction does not change during the different phases of tumor growth. "
|2.||Hairy Cell Leukemia
01/01/2006 - "Its mechanism of action involves binding to CD22, being internalized into the target cell by endocytosis, being processed to generate a free toxin fragment which is translocated into the cytoplasm, and finally induction of cell death by catalytic inactivation of elongation factor 2. In phase-I testing BL22 was very active in chemoresistant hairy-cell leukemia (HCL), with 19 (61%) of 31 patients achieving complete remission (CR). "
09/01/2014 - "After TAC, all hypertrophic remodeling patterns known in human disease were observed: 1) low-flow, low-gradient with preserved ejection fraction (EF); 2) concentric hypertrophy with normal EF and flow; 3) concentric hypertrophy with moderately decreased EF and/or flow; 4) eccentric hypertrophy with normal EF and flow; 5) eccentric hypertrophy with moderately decreased EF and/or flow; and 6) eccentric hypertrophy with severely depressed EF. "
07/01/2009 - "This enhanced growth of AMPKalpha1-deficient muscle was accompanied by increased phosphorylation of mTOR signaling downstream targets and decreased phosphorylation of eukaryotic elongation factor 2. These results demonstrate that AMPKalpha1 plays an important role in limiting skeletal muscle overgrowth during hypertrophy through inhibition of the mTOR-signaling pathway."
01/01/2002 - "Hypertrophy under additional IGF-1 was combined with a shift of the EF-2 variants to basic subtypes (p < 0.01). "
08/01/2014 - "In this study, we aimed to investigate the role of ERK in translational control during CB-induced muscular hypertrophy by measuring time-dependent changes in the phosphorylation statuses of ERK, p70 ribosomal S6 kinase (p70S6K; an indicator of mTORC1 activity), 4E-binding protein 1 (4E-BP1), eukaryotic elongation factor 2 (eEF2), and other related signaling molecules in rat gastrocnemius muscles. "
02/01/2007 - "In kidney glomerular epithelial cells, high glucose (30 mM), but not equimolar mannitol, stimulated de novo protein synthesis and induced hypertrophy in association with increased phosphorylation of eukaryotic initiation factor 4E binding protein 1 and decreased phosphorylation of eukaryotic elongation factor 2, regulatory events in mRNA translation. "
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/15/1998 - "The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene."
07/01/2005 - "Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells."
05/01/2014 - "In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. "
|5.||AIDS-Related Complex (ARC)
07/10/2008 - "Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD."
11/12/2008 - "LTD evoked by activation of metabotropic glutamate receptors depends on rapid Arc translation controlled by elongation factor 2. Bramham and colleagues have shown that sustained translation of newly induced Arc mRNA is necessary for cofilin phosphorylation and stable expansion of the F-actin cytoskeleton underlying LTP consolidation in the dentate gyrus of live rats. "
08/01/2009 - "In this study, BDNF treatment alone induced the activation of the phosphatidylinositol 3-kinase-Akt-mammlian target of rapamycin (PI3K-Akt-mTOR) signaling pathway, the phosphorylation of eukaryotic initiation factor 4E binding protein (4EBP1) and p70 ribosomal S6 kinase (p70S6K), the dephosphorylation of eukaryotic elongation factor 2 (eEF2), and the expression of Arc. "
|1.||Peptide Initiation Factors (Initiation Factor)
|2.||Protein Kinases (Protein Kinase)
|3.||Proteasome Endopeptidase Complex (Proteasome)
|5.||Caspase 3 (Caspase-3)
|6.||Double-Stranded RNA (RNA, Double Stranded)
|8.||Ribosomal Protein S6 Kinases (S6 Kinase)
|9.||70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)
|10.||Proteins (Proteins, Gene)